- Home
- DXLG vs TNYA Comparison
DXLG vs TNYA Comparison
Compare DXLG & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- TNYA
- Stock Information
- Founded
- DXLG 1976
- TNYA 2016
- Country
- DXLG United States
- TNYA United States
- Employees
- DXLG N/A
- TNYA N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- DXLG Consumer Discretionary
- TNYA Health Care
- Exchange
- DXLG Nasdaq
- TNYA Nasdaq
- Market Cap
- DXLG 64.0M
- TNYA 73.8M
- IPO Year
- DXLG 1987
- TNYA 2021
- Fundamental
- Price
- DXLG $1.03
- TNYA $0.58
- Analyst Decision
- DXLG Strong Buy
- TNYA Strong Buy
- Analyst Count
- DXLG 1
- TNYA 5
- Target Price
- DXLG $2.50
- TNYA $8.60
- AVG Volume (30 Days)
- DXLG 270.8K
- TNYA 2.5M
- Earning Date
- DXLG 05-29-2025
- TNYA 08-07-2025
- Dividend Yield
- DXLG N/A
- TNYA N/A
- EPS Growth
- DXLG N/A
- TNYA N/A
- EPS
- DXLG N/A
- TNYA N/A
- Revenue
- DXLG $457,059,000.00
- TNYA N/A
- Revenue This Year
- DXLG N/A
- TNYA N/A
- Revenue Next Year
- DXLG $3.56
- TNYA N/A
- P/E Ratio
- DXLG N/A
- TNYA N/A
- Revenue Growth
- DXLG N/A
- TNYA N/A
- 52 Week Low
- DXLG $0.90
- TNYA $0.36
- 52 Week High
- DXLG $3.93
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- DXLG 43.76
- TNYA 53.16
- Support Level
- DXLG $1.00
- TNYA $0.56
- Resistance Level
- DXLG $1.16
- TNYA $0.64
- Average True Range (ATR)
- DXLG 0.08
- TNYA 0.06
- MACD
- DXLG -0.01
- TNYA -0.00
- Stochastic Oscillator
- DXLG 15.52
- TNYA 41.37
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.